vs
Apellis Pharmaceuticals, Inc.（APLS）与FIRST BANCORP（FBP）财务数据对比。点击上方公司名可切换其他公司
FIRST BANCORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$257.2M vs $199.9M），FIRST BANCORP净利率更高（33.9% vs -29.5%，领先63.4%），FIRST BANCORP同比增速更快（6.5% vs -5.9%），FIRST BANCORP自由现金流更多（$103.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 5.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
第一中西部银行总部位于美国伊利诺伊州芝加哥市，地处奥黑尔机场东侧，其前身可追溯至伊利诺伊州乔利埃特市。发展至今，该行服务范围覆盖芝加哥众多郊区，包括印第安纳州西北部、伊利诺伊州南部、威斯康星州东南部以及含爱荷华州在内的四城地区，是美国规模最大的银行机构之一。
APLS vs FBP — 直观对比
营收规模更大
FBP
是对方的1.3倍
$199.9M
营收增速更快
FBP
高出12.4%
-5.9%
净利率更高
FBP
高出63.4%
-29.5%
自由现金流更多
FBP
多$117.5M
$-14.3M
两年增速更快
APLS
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $257.2M |
| 净利润 | $-59.0M | $87.1M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 41.7% |
| 净利率 | -29.5% | 33.9% |
| 营收同比 | -5.9% | 6.5% |
| 净利润同比 | -62.2% | 15.1% |
| 每股收益（稀释后） | $-0.40 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFBP
| Q4 25 | $199.9M | $257.2M | ||
| Q3 25 | $458.6M | $248.7M | ||
| Q2 25 | $178.5M | $246.8M | ||
| Q1 25 | $166.8M | $248.1M | ||
| Q4 24 | $212.5M | $241.5M | ||
| Q3 24 | $196.8M | $234.6M | ||
| Q2 24 | $199.7M | $231.7M | ||
| Q1 24 | $172.3M | $230.5M |
净利润APLSFBP
| Q4 25 | $-59.0M | $87.1M | ||
| Q3 25 | $215.7M | $100.5M | ||
| Q2 25 | $-42.2M | $80.2M | ||
| Q1 25 | $-92.2M | $77.1M | ||
| Q4 24 | $-36.4M | $75.7M | ||
| Q3 24 | $-57.4M | $73.7M | ||
| Q2 24 | $-37.7M | $75.8M | ||
| Q1 24 | $-66.4M | $73.5M |
营业利润率APLSFBP
| Q4 25 | -25.6% | 41.7% | ||
| Q3 25 | 48.7% | 42.7% | ||
| Q2 25 | -18.6% | 41.7% | ||
| Q1 25 | -50.0% | 40.4% | ||
| Q4 24 | -12.3% | 39.8% | ||
| Q3 24 | -24.0% | 41.1% | ||
| Q2 24 | -14.7% | 43.8% | ||
| Q1 24 | -36.0% | 42.3% |
净利率APLSFBP
| Q4 25 | -29.5% | 33.9% | ||
| Q3 25 | 47.0% | 40.4% | ||
| Q2 25 | -23.6% | 32.5% | ||
| Q1 25 | -55.3% | 31.1% | ||
| Q4 24 | -17.1% | 31.4% | ||
| Q3 24 | -29.2% | 31.4% | ||
| Q2 24 | -18.9% | 32.7% | ||
| Q1 24 | -38.5% | 31.9% |
每股收益（稀释后）APLSFBP
| Q4 25 | $-0.40 | $0.55 | ||
| Q3 25 | $1.67 | $0.63 | ||
| Q2 25 | $-0.33 | $0.50 | ||
| Q1 25 | $-0.74 | $0.47 | ||
| Q4 24 | $-0.30 | $0.46 | ||
| Q3 24 | $-0.46 | $0.45 | ||
| Q2 24 | $-0.30 | $0.46 | ||
| Q1 24 | $-0.54 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $290.0M |
| 股东权益账面价值 | $370.1M | $2.0B |
| 总资产 | $1.1B | $19.1B |
| 负债/权益比越低杠杆越低 | — | 0.15× |
8季度趋势，按日历期对齐
现金及短期投资APLSFBP
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSFBP
| Q4 25 | — | $290.0M | ||
| Q3 25 | — | $290.0M | ||
| Q2 25 | — | $320.0M | ||
| Q1 25 | — | $331.1M | ||
| Q4 24 | — | $561.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSFBP
| Q4 25 | $370.1M | $2.0B | ||
| Q3 25 | $401.2M | $1.9B | ||
| Q2 25 | $156.3M | $1.8B | ||
| Q1 25 | $164.2M | $1.8B | ||
| Q4 24 | $228.5M | $1.7B | ||
| Q3 24 | $237.1M | $1.7B | ||
| Q2 24 | $264.3M | $1.5B | ||
| Q1 24 | $266.7M | $1.5B |
总资产APLSFBP
| Q4 25 | $1.1B | $19.1B | ||
| Q3 25 | $1.1B | $19.3B | ||
| Q2 25 | $821.4M | $18.9B | ||
| Q1 25 | $807.3M | $19.1B | ||
| Q4 24 | $885.1M | $19.3B | ||
| Q3 24 | $901.9M | $18.9B | ||
| Q2 24 | $904.5M | $18.9B | ||
| Q1 24 | $831.9M | $18.9B |
负债/权益比APLSFBP
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $107.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $103.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 40.1% |
| 资本支出强度资本支出/营收 | 0.1% | 1.6% |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $437.5M |
8季度趋势，按日历期对齐
经营现金流APLSFBP
| Q4 25 | $-14.2M | $107.3M | ||
| Q3 25 | $108.5M | $137.6M | ||
| Q2 25 | $4.4M | $95.4M | ||
| Q1 25 | $-53.4M | $108.2M | ||
| Q4 24 | $19.4M | $96.8M | ||
| Q3 24 | $34.1M | $118.0M | ||
| Q2 24 | $-8.3M | $71.1M | ||
| Q1 24 | $-133.0M | $118.2M |
自由现金流APLSFBP
| Q4 25 | $-14.3M | $103.2M | ||
| Q3 25 | $108.3M | $134.8M | ||
| Q2 25 | $4.4M | $92.8M | ||
| Q1 25 | $-53.4M | $106.7M | ||
| Q4 24 | $19.3M | $95.2M | ||
| Q3 24 | — | $115.4M | ||
| Q2 24 | $-8.4M | $69.4M | ||
| Q1 24 | $-133.3M | $114.1M |
自由现金流率APLSFBP
| Q4 25 | -7.1% | 40.1% | ||
| Q3 25 | 23.6% | 54.2% | ||
| Q2 25 | 2.5% | 37.6% | ||
| Q1 25 | -32.0% | 43.0% | ||
| Q4 24 | 9.1% | 39.4% | ||
| Q3 24 | — | 49.2% | ||
| Q2 24 | -4.2% | 30.0% | ||
| Q1 24 | -77.3% | 49.5% |
资本支出强度APLSFBP
| Q4 25 | 0.1% | 1.6% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.0% | 1.1% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.2% | 1.8% |
现金转化率APLSFBP
| Q4 25 | — | 1.23× | ||
| Q3 25 | 0.50× | 1.37× | ||
| Q2 25 | — | 1.19× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.28× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 0.94× | ||
| Q1 24 | — | 1.61× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FBP
| Consumer Retail Banking Segment | $171.5M | 67% |
| Commercial And Corporate Segment | $46.9M | 18% |
| Mortgage Banking Segment | $22.4M | 9% |
| Virgin Islands Operations Segment | $18.6M | 7% |
